Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
In treating moderate to severe anemia of chronic kidney disease (CKD), oral iron is effective only in a minority of nondialysis patients. Intravenous iron is more effective and can raise levels of hemoglobin even without the use of erythropoiesis-stimulating agents (ESAs). Unfortunately, the current assays of iron status that are presently widely available are not especially helpful in predicting response. In patients on dialysis, i.v. iron is effective over a wide range of serum ferritin from <100 ng/ml to 800 ng/ml. None of the three available randomized controlled trials comparing oral with i.v. iron showed evidence of nephrotoxicity caused by i.v. iron. Iron deficiency is a risk factor for thrombocytosis and should, wherever possible, be avoided. Optimal coadministration of iron may reduce the risk for ESA-driven cardiovascular events. Increased total body iron stores (imperfectly reflected by serum ferritin levels in CKD) do not appear to be related to such events or hospitalization in CKD; it is unclear what other risk factors and mechanisms need to be considered. In the appreciable proportion of patients with both renal and cardiac dysfunction, management is further complicated by a vicious circle (which can be characterized as cardiorenal anemia syndrome) in which CKD, heart failure, and anemia exacerbate each other. In such patients, correction of anemia appears to improve cardiac function and quality of life without a greater risk for adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Andrews, N. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912233412607 · Cited by 2,130 · cited 2×
“Figure 3. The balance of iron in the healthy adult: Distribution of iron in adults [ 24 ].”
BackgroundBesarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Self-citationIRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK
Sullivan, J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92463-6 · Cited by 969
Assessing Iron Status: Beyond Serum Ferritin and Transferrin Saturation
Wish, J. B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01490506 · Cited by 556
Intravenous Iron Alone for the Treatment of Anemia in Patients With Chronic Heart Failure
Bolger, A. P., Bartlett, F. R., Penston, H. S., O’Leary, J., Pollock, N., Kaprielian, R., & Chapman, C. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.015 · Cited by 292 · cited 1×
“iron alone in anemic CHF patients, two uncontrolled studies [ 73 , 74], and one doubleblind placebo-controlled study [74], have shown improved Hb, LVEF, NYHA class, left ventricular hypertrophy, and dilation, reduced heart rate and pulmonary artery pressure, and superior quality of life, exercise capacity, renal funct…”
ResultHepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia
Rivera, S., Liu, L., Nemeth, E., Gabayan, V., Sorensen, O. E., & Ganz, T. (2005) · Blood · doi:10.1182/blood-2004-08-3375 · Cited by 196 · cited 2×
“In general, a U-shaped curve exists, with a nadir for eachHbstratumfornochangeinHb,withriskincreasingas the prevailing Hb decreases from 13 g/dl to 10 g/dl [ 20 ].”
BackgroundChronic Iron Administration Increases Vascular Oxidative Stress and Accelerates Arterial Thrombosis
Day, S. M., Duquaine, D., Mundada, L. V., Menon, R. G., Khan, B. V., Rajagopalan, S., & Fay, W. P. (2003) · Circulation · doi:10.1161/01.cir.0000066910.02844.d0 · Cited by 192
Cited by
Iron deficiency in chronic heart failure: an international pooled analysis
Klip, I. T., Comin-Colet, J., Voors, A. A., Ponikowski, P., Enjuanes, C., Banasiak, W., Lok, D. J., Rosentryt, P., Torrens, A., Polonski, L., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.01.017 · Cited by 736
Disordered Iron Homeostasis in Chronic Heart Failure
Okonko, D. O., Mandal, A. K. J., Missouris, C. G., & Poole-Wilson, P. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.04.040 · Cited by 373
Silverberg, D. S. (2011) · Heart Failure Reviews · doi:10.1007/s10741-010-9194-2 · Cited by 48
“Iron deficiency of any cause can cause increased production and activation of platelets and may thus cause a hypercoagulable state [15].”
Self-citation
Metadata
- Authors
- Besarab, A., Hörl, W. H., & Silverberg, D.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-09-01
- Volume
- 14
- Issue
- S1
- Pages
- 22-33
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2104604838
- Cited by
- 69
- References
- 8
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome. https://app.cochat.ai/papers/10.1634/theoncologist.2009-s1-22
- The paper
- Besarab, A., Hörl, W. H., & Silverberg, D. (2009). Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome. The Oncologist. https://doi.org/10.1634/theoncologist.2009-s1-22
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.